Mostrar el registro sencillo del ítem

Amoxapine as an atypical antipsychotic: a comparative study vs risperidone

dc.creatorApiquian, R.
dc.creatorFresan, A.
dc.creatorUlloa, R.E.
dc.creatorDe la Fuente-Sandoval, C.
dc.creatorHerrera-Estrella, M.
dc.creatorVazquez, A.
dc.creatorNicolini, H.
dc.creatorKapur, S.
dc.date.accessioned2017-06-29T04:36:50Z
dc.date.available2017-06-29T04:36:50Z
dc.date.issued2005es_ES
dc.identifier470es_ES
dc.identifier.issn0893-133Xes_ES
dc.identifier.urihttp://repositorio.inprf.gob.mx/handle/123456789/5158
dc.identifier.urihttps://doi.org/10.1038/sj.npp.1300796es_ES
dc.language.isoenges_ES
dc.relation30 (12) 2236-2244 p.es_ES
dc.relationversión del editores_ES
dc.rightsacceso cerradoes_ES
dc.titleAmoxapine as an atypical antipsychotic: a comparative study vs risperidonees_ES
dc.typearticlees_ES
dc.contributor.affiliationDepartment of Psychiatry, National Institute of Neurology and Neurosurgery Manuel Velasco Suarez, Av. Insurgentes Sur 3877, Mexico City, 14296 Mexico.es_ES
dc.contributor.emailrogelioapiquian@yahoo.com.mxes_ES
dc.relation.jnabreviadoNEUROPSYCHOPHARMACOLOGYes_ES
dc.relation.journalNeuropsychopharmacologyes_ES
dc.identifier.placeEstados Unidoses_ES
dc.date.published2005es_ES
dc.identifier.organizacionInstituto Nacional de Psiquiatría Ramón de la Fuente Muñizes_ES
dc.identifier.eissn0006-3223es_ES
dc.identifier.doi10.1038/sj.npp.1300796es_ES
dc.description.monthDices_ES
dc.description.abstractotrodiomaAmoxapine is marketed as an antidepressant. However, its in-vitro profile, receptor occupancy and preclinical effects are very similar to atypical antipsychotics. Amoxapine has also shown efficacy as an atypical antipsychotic in open trials. The objective of this study was to compare the antipsychotic and side effect profile of amoxapine and risperidone in a randomised assignment, standardized dosing, double-blind trial of acutely psychotic patients with schizophrenia. A total of 48 schizophrenic patients were enrolled and randomized in a double-blind 6-week trial to receive either risperidone (up to 5 mg/day) or amoxapine (up to 250 mg/day). Positive, negative, affective symptoms and motor side effects were measured using standardized weekly assessments. Prolactin levels were also determined at baseline and at the end of the study. A total of 39 patients (amoxapine, n=22; risperidone, n=21) completed the trial. Both pharmacological treatments, amoxapine 228.0 mg/day (SD=34.6) and risperidone 4.5 mg/day (SD=0.7), showed equivalent improvement in positive, negative, and depressive symptoms. Amoxapine was associated with less EPS and less prolactin elevation than risperidone. These data support previous reports about the efficacy of amoxapine as an atypical antipsychotic. Since amoxapine is off-patent, it may be a valuable low-cost alternative to new atypical antipsychotics, particularly in low-income countries where the majority of the patients are still treated with typical antipsychotics.es_ES
dc.subject.kwAmoxapinaes_ES
dc.subject.kwRisperidonaes_ES
dc.subject.kwEsquizofreniaes_ES
dc.subject.kwAtípicoes_ES
dc.subject.kwAntipsicóticoses_ES
dc.subject.koRisperidonees_ES
dc.subject.koSchizopheniaes_ES
dc.subject.koAtypicales_ES
dc.subject.koAntipsychotices_ES
dc.subject.koAmoxapinees_ES


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem